Cargando…

Future trends in incidence and long-term survival of metastatic cancer in the United States

BACKGROUND: Previous studies have demonstrated epidemiological trends in individual metastatic cancer subtypes; however, research forecasting long-term incidence trends and projected survivorship of metastatic cancers is lacking. We assess the burden of metastatic cancer to 2040 by (1) characterizin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hudock, Nicholas L., Mani, Kyle, Khunsriraksakul, Chachrit, Walter, Vonn, Nekhlyudov, Larissa, Wang, Ming, Lehrer, Eric J., Hudock, Maria R., Liu, Dajiang J., Spratt, Daniel E., Zaorsky, Nicholas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224927/
https://www.ncbi.nlm.nih.gov/pubmed/37244961
http://dx.doi.org/10.1038/s43856-023-00304-x
_version_ 1785050296533123072
author Hudock, Nicholas L.
Mani, Kyle
Khunsriraksakul, Chachrit
Walter, Vonn
Nekhlyudov, Larissa
Wang, Ming
Lehrer, Eric J.
Hudock, Maria R.
Liu, Dajiang J.
Spratt, Daniel E.
Zaorsky, Nicholas G.
author_facet Hudock, Nicholas L.
Mani, Kyle
Khunsriraksakul, Chachrit
Walter, Vonn
Nekhlyudov, Larissa
Wang, Ming
Lehrer, Eric J.
Hudock, Maria R.
Liu, Dajiang J.
Spratt, Daniel E.
Zaorsky, Nicholas G.
author_sort Hudock, Nicholas L.
collection PubMed
description BACKGROUND: Previous studies have demonstrated epidemiological trends in individual metastatic cancer subtypes; however, research forecasting long-term incidence trends and projected survivorship of metastatic cancers is lacking. We assess the burden of metastatic cancer to 2040 by (1) characterizing past, current, and forecasted incidence trends, and (2) estimating odds of long-term (5-year) survivorship. METHODS: This retrospective, serial cross-sectional, population-based study used registry data from the Surveillance, Epidemiology, and End Results (SEER 9) database. Average annual percentage change (AAPC) was calculated to describe cancer incidence trends from 1988 to 2018. Autoregressive integrating moving average (ARIMA) models were used to forecast the distribution of primary metastatic cancer and metastatic cancer to specific sites from 2019 to 2040 and JoinPoint models were fitted to estimate mean projected annual percentage change (APC). RESULTS: The average annual percent change (AAPC) in incidence of metastatic cancer decreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease by 0.70 per 100,000 individuals (2018–2040). Analyses predict a decrease in metastases to liver (APC = −3.40, 95% CI [−3.50, −3.30]), lung (APC (2019–2030) = −1.90, 95% CI [−2.90, −1.00]); (2030–2040) = −3.70, 95% CI [−4.60, −2.80]), bone (APC = −4.00, 95% CI [−4.30, −3.70]), and brain (APC = −2.30, 95% CI [−2.60, −2.00]). By 2040, patients with metastatic cancer are predicted to have 46.7% greater odds of long-term survivorship, driven by increasing plurality of patients with more indolent forms of metastatic disease. CONCLUSIONS: By 2040, the distribution of metastatic cancer patients is predicted to shift in predominance from invariably fatal to indolent cancers subtypes. Continued research on metastatic cancers is important to guide health policy and clinical intervention efforts, and direct allocations of healthcare resources.
format Online
Article
Text
id pubmed-10224927
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102249272023-05-29 Future trends in incidence and long-term survival of metastatic cancer in the United States Hudock, Nicholas L. Mani, Kyle Khunsriraksakul, Chachrit Walter, Vonn Nekhlyudov, Larissa Wang, Ming Lehrer, Eric J. Hudock, Maria R. Liu, Dajiang J. Spratt, Daniel E. Zaorsky, Nicholas G. Commun Med (Lond) Article BACKGROUND: Previous studies have demonstrated epidemiological trends in individual metastatic cancer subtypes; however, research forecasting long-term incidence trends and projected survivorship of metastatic cancers is lacking. We assess the burden of metastatic cancer to 2040 by (1) characterizing past, current, and forecasted incidence trends, and (2) estimating odds of long-term (5-year) survivorship. METHODS: This retrospective, serial cross-sectional, population-based study used registry data from the Surveillance, Epidemiology, and End Results (SEER 9) database. Average annual percentage change (AAPC) was calculated to describe cancer incidence trends from 1988 to 2018. Autoregressive integrating moving average (ARIMA) models were used to forecast the distribution of primary metastatic cancer and metastatic cancer to specific sites from 2019 to 2040 and JoinPoint models were fitted to estimate mean projected annual percentage change (APC). RESULTS: The average annual percent change (AAPC) in incidence of metastatic cancer decreased by 0.80 per 100,000 individuals (1988–2018) and we forecast an APC decrease by 0.70 per 100,000 individuals (2018–2040). Analyses predict a decrease in metastases to liver (APC = −3.40, 95% CI [−3.50, −3.30]), lung (APC (2019–2030) = −1.90, 95% CI [−2.90, −1.00]); (2030–2040) = −3.70, 95% CI [−4.60, −2.80]), bone (APC = −4.00, 95% CI [−4.30, −3.70]), and brain (APC = −2.30, 95% CI [−2.60, −2.00]). By 2040, patients with metastatic cancer are predicted to have 46.7% greater odds of long-term survivorship, driven by increasing plurality of patients with more indolent forms of metastatic disease. CONCLUSIONS: By 2040, the distribution of metastatic cancer patients is predicted to shift in predominance from invariably fatal to indolent cancers subtypes. Continued research on metastatic cancers is important to guide health policy and clinical intervention efforts, and direct allocations of healthcare resources. Nature Publishing Group UK 2023-05-27 /pmc/articles/PMC10224927/ /pubmed/37244961 http://dx.doi.org/10.1038/s43856-023-00304-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hudock, Nicholas L.
Mani, Kyle
Khunsriraksakul, Chachrit
Walter, Vonn
Nekhlyudov, Larissa
Wang, Ming
Lehrer, Eric J.
Hudock, Maria R.
Liu, Dajiang J.
Spratt, Daniel E.
Zaorsky, Nicholas G.
Future trends in incidence and long-term survival of metastatic cancer in the United States
title Future trends in incidence and long-term survival of metastatic cancer in the United States
title_full Future trends in incidence and long-term survival of metastatic cancer in the United States
title_fullStr Future trends in incidence and long-term survival of metastatic cancer in the United States
title_full_unstemmed Future trends in incidence and long-term survival of metastatic cancer in the United States
title_short Future trends in incidence and long-term survival of metastatic cancer in the United States
title_sort future trends in incidence and long-term survival of metastatic cancer in the united states
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224927/
https://www.ncbi.nlm.nih.gov/pubmed/37244961
http://dx.doi.org/10.1038/s43856-023-00304-x
work_keys_str_mv AT hudocknicholasl futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates
AT manikyle futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates
AT khunsriraksakulchachrit futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates
AT waltervonn futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates
AT nekhlyudovlarissa futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates
AT wangming futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates
AT lehrerericj futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates
AT hudockmariar futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates
AT liudajiangj futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates
AT sprattdaniele futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates
AT zaorskynicholasg futuretrendsinincidenceandlongtermsurvivalofmetastaticcancerintheunitedstates